Fresenius SE & Co. KGaA (FRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fresenius SE & Co. KGaA (FRE) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€756.00 Million ≈ $883.84 Million USD) by net assets (€19.27 Billion ≈ $22.53 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FRE equity financing ratio to measure how much of total assets are equity-financed.
Fresenius SE & Co. KGaA - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Fresenius SE & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Fresenius SE & Co. KGaA's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Fresenius SE & Co. KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fresenius SE & Co. KGaA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eternal Limited
NSE:ETERNAL
|
-0.003x |
|
George Weston Limited
TO:WN
|
0.304x |
|
VICI Properties Inc
NYSE:VICI
|
0.022x |
|
Chunghwa Telecom Co. Ltd
F:CHWD
|
0.080x |
|
GE HealthCare Technologies Inc.
NASDAQ:GEHC
|
0.027x |
|
DENSO CORP. ADR 4
F:DNOA
|
N/A |
|
FIRSTRAND ADR/ 10 RC -01
F:FSR
|
N/A |
|
Caseys General Stores Inc
NASDAQ:CASY
|
0.067x |
Annual Cash Flow Conversion Efficiency for Fresenius SE & Co. KGaA (2002–2024)
The table below shows the annual cash flow conversion efficiency of Fresenius SE & Co. KGaA from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Fresenius SE & Co. KGaA (FRE) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €20.29 Billion ≈ $23.72 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.121x | -46.81% |
| 2023-12-31 | €19.65 Billion ≈ $22.97 Billion |
€4.46 Billion ≈ $5.21 Billion |
0.227x | +74.03% |
| 2022-12-31 | €32.22 Billion ≈ $37.67 Billion |
€4.20 Billion ≈ $4.91 Billion |
0.130x | -24.85% |
| 2021-12-31 | €29.29 Billion ≈ $34.24 Billion |
€5.08 Billion ≈ $5.94 Billion |
0.173x | -31.11% |
| 2020-12-31 | €26.02 Billion ≈ $30.42 Billion |
€6.55 Billion ≈ $7.66 Billion |
0.252x | +56.91% |
| 2019-12-31 | €26.58 Billion ≈ $31.07 Billion |
€4.26 Billion ≈ $4.98 Billion |
0.160x | +7.19% |
| 2018-12-31 | €25.01 Billion ≈ $29.24 Billion |
€3.74 Billion ≈ $4.37 Billion |
0.150x | -17.45% |
| 2017-12-31 | €21.72 Billion ≈ $25.39 Billion |
€3.94 Billion ≈ $4.60 Billion |
0.181x | +9.57% |
| 2016-12-31 | €21.60 Billion ≈ $25.26 Billion |
€3.57 Billion ≈ $4.18 Billion |
0.165x | -5.77% |
| 2015-12-31 | €18.95 Billion ≈ $22.15 Billion |
€3.33 Billion ≈ $3.89 Billion |
0.176x | +9.78% |
| 2014-12-31 | €16.16 Billion ≈ $18.90 Billion |
€2.58 Billion ≈ $3.02 Billion |
0.160x | -5.34% |
| 2013-12-31 | €13.73 Billion ≈ $16.05 Billion |
€2.32 Billion ≈ $2.71 Billion |
0.169x | -8.83% |
| 2012-12-31 | €13.16 Billion ≈ $15.38 Billion |
€2.44 Billion ≈ $2.85 Billion |
0.185x | +16.05% |
| 2011-12-31 | €10.58 Billion ≈ $12.37 Billion |
€1.69 Billion ≈ $1.97 Billion |
0.160x | -26.10% |
| 2010-12-31 | €8.84 Billion ≈ $10.34 Billion |
€1.91 Billion ≈ $2.23 Billion |
0.216x | +6.47% |
| 2009-12-31 | €7.65 Billion ≈ $8.95 Billion |
€1.55 Billion ≈ $1.82 Billion |
0.203x | +31.20% |
| 2008-12-31 | €6.94 Billion ≈ $8.12 Billion |
€1.07 Billion ≈ $1.26 Billion |
0.155x | -60.16% |
| 2007-12-31 | €3.34 Billion ≈ $3.90 Billion |
€1.30 Billion ≈ $1.52 Billion |
0.388x | +14.48% |
| 2006-12-31 | €3.10 Billion ≈ $3.63 Billion |
€1.05 Billion ≈ $1.23 Billion |
0.339x | +20.70% |
| 2005-12-31 | €2.78 Billion ≈ $3.25 Billion |
€780.00 Million ≈ $911.90 Million |
0.281x | -47.07% |
| 2004-12-31 | €1.60 Billion ≈ $1.87 Billion |
€851.00 Million ≈ $994.91 Million |
0.531x | +119.88% |
| 2003-12-31 | €3.21 Billion ≈ $3.76 Billion |
€776.00 Million ≈ $907.23 Million |
0.241x | +16.70% |
| 2002-12-31 | €3.37 Billion ≈ $3.94 Billion |
€697.00 Million ≈ $814.87 Million |
0.207x | -- |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more